News & Updates
Filter by Specialty:
CATALYST sparks signals favouring namilumab for COVID-19
In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.
CATALYST sparks signals favouring namilumab for COVID-19
19 Jan 2022
Zuranolone for sleeplessness promising in early study
The orally bioavailable, investigational neuroactive steroid zuranolone appears to be beneficial in the treatment of insomnia, producing improvements in sleep measures, including sleep efficiency, duration of awakenings, and total sleep time in adults, according to the results of a phase I study.
Zuranolone for sleeplessness promising in early study
19 Jan 2022
Fluvoxamine may prevent COVID-19 hospitalization
Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.
Fluvoxamine may prevent COVID-19 hospitalization
18 Jan 2022
Can atorvastatin save COVID-19 patients in intensive care?
Use of atorvastatin in adults with COVID-19 admitted to the intensive care unit (ICU) is safe but does not result in a marked decrease in the composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all-cause mortality, a study has shown.
